GET INVOLVED

Contact Us

WE ARE ALWAYS THINKING OF WHAT COULD BE POSSIBLE.

CuboPharm’s patented cubosome platform is a lipid-based nanoparticle system designed to overcome key challenges in drug delivery — particularly for compounds with poor solubility or high first-pass metabolism.

Our sublingual, orally disintegrating formulation enables direct systemic absorption, bypassing the liver and minimizing the formation of toxic metabolites.

We aim to bring these ideas into reality through collaboration with like-minded organisations.

Development Milestones

  • Optimised formulation & process development
  • Phase studies at the Australian Synchrotron (complete database)
  • In vitro diffusion and permeation Studies (MIPS) (formulation selection)
  • Demonstrated efficacy in statin-intolerant patients (SARSI)
  • Manufacturing 1st registration batch
  • PK comparison: ODT 5mg vs oral Crestor 40mg
  • 36-month stability data and SAS B Authorised Prescriber Scheme

Clinical and Regulatory Milestones

  • 181% bioavailability of 5mg Rosuvastatin ODT vs oral Crestor 5mg
  • 62% reduction in toxic Rosuvastatin lactone metabolite
  • TGA SAS-B approved since 2021
  • 70+ patients dosed with high tolerability (SAS B )
    – 95% reduction in statin-associated myopathy symptoms
    – 42% reduction in LDL-C
    – 29% reduction in total cholesterol

BUSINESS MODEL

  • Licensing

  • Strategic Partnership

Market Opportunity

Global statins market: $15.4B (2023) → projected $20B by 2032 Rosuvastatin ODT SL offers a differentiated therapeutic option with platform potential across multiple APIs

Patent Strategy

Comprehensive IP portfolio covering Formulation, Drug delivery mechanism and Process of manufacture. Strong global positioning for competitive advantage in the statins market

GET INVOLVED

CuboPharm is actively seeking investment, licensing, and distribution partners to bring our breakthrough Cubosome platform to market. Join us in improving outcomes for patients around the world.
If you share our vision, we invite you to connect and explore how we can work together.
Contact Us